Cargando…

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases

BACKGROUND: Tamoxifen has anti-oestrogenic and anti-tumour activity in the breast, but is oestrogenic and carcinogenic in the endometrium. It can induce experimental tumours by both hormonal and DNA-damaging mechanisms, but its carcinogenic mode of action in human endometrium remains unclear. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagy, E, Gajjar, K B, Patel, I I, Taylor, S, Martin-Hirsch, P L, Stringfellow, H F, Martin, F L, Phillips, D H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056065/ https://www.ncbi.nlm.nih.gov/pubmed/24853176 http://dx.doi.org/10.1038/bjc.2014.263

Ejemplares similares

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

MAL promoter hypermethylation as a novel prognostic marker in gastric cancer
por: Buffart, T E, et al.
Publicado: (2008)

SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response
por: Cheetham, S, et al.
Publicado: (2008)

PTEN regulates colorectal epithelial apoptosis through Cdc42 signalling
por: Deevi, R, et al.
Publicado: (2011)

An α-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen
por: Andersen, T T, et al.
Publicado: (2007)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer
por: Xu, S, et al.
Publicado: (2015)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
por: Smith, G, et al.
Publicado: (2010)

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model
por: Delord, J-P, et al.
Publicado: (2010)

Impaired TNFα-induced A20 expression in E1A/Ras-transformed cells
por: Huang, H-L, et al.
Publicado: (2009)

Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells
por: McCloy, R A, et al.
Publicado: (2013)

Regulation of tamoxifen sensitivity by a PAK1–EBP1 signalling pathway in breast cancer
por: Ghosh, A, et al.
Publicado: (2013)

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells
por: Li, C, et al.
Publicado: (2005)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate
por: Scandlyn, M J, et al.
Publicado: (2008)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling
por: Dubrovska, A, et al.
Publicado: (2012)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer
por: Qin, R, et al.
Publicado: (2015)

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression
por: Kashiwagi, Eiji, et al.
Publicado: (2018)

Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
por: Han, Sheng, et al.
Publicado: (2017)

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
por: García-Martínez, J M, et al.
Publicado: (2011)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation
por: Groenendijk, Floris H., et al.
Publicado: (2010)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study
por: Martin, N K, et al.
Publicado: (2012)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Fas/Fas ligand regulation mediates cell death in human Ewing's sarcoma cells treated with melatonin
por: García-Santos, G, et al.
Publicado: (2012)

Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells
por: Martín, V, et al.
Publicado: (2013)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

Harmonisation of biobanking standards in endometrial cancer research
por: Adishesh, M, et al.
Publicado: (2017)

Stat3 activation in human endometrial and cervical cancers
por: Chen, C-L, et al.
Publicado: (2007)

Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration
por: Lee, C M, et al.
Publicado: (2006)

Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-(13)C]pyruvate and [1,4-(13)C(2)]fumarate
por: Witney, T H, et al.
Publicado: (2010)

In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin
por: Gyémánt, N, et al.
Publicado: (2010)

βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer
por: Christoph, D C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ef1k34ecg3ugqr7nq9b0ftbntj